{"Clinical Trial ID": "NCT00407888", "Intervention": ["INTERVENTION 1:", "Bras I", "Patients receive high-dose chemotherapy including doxorubicin IV hydrochloride for 10 to 15 minutes on day 1, oral cyclophosphamide once daily on days 1 to 7 and filgrastim subcutaneously on days 2 to 7. Courses are repeated every 7 days for 12 weeks in the absence of disease progression or unacceptable toxicity. Starting a week later, patients are then given a formulation of nanoparticles stabilized with paclitaxel IV albumin for 30 minutes once weekly for 12 weeks in the absence of disease progression or unacceptable toxicity.", "Doxorubicin hydrochloride: IV", "cyclophosphamide: administered orally", "- filgrastim: seen SC", "Formulation of nanoparticles stabilized by paclitaxel albumin:", "Trastuzumab: under IV", "Analysis of laboratory biomarkers: related studies", "Quality of Life Assessment: Auxiliary Studies"], "Eligibility": ["Incorporation criteria:", "Have a histologically confirmed diagnosis of primary breast carcinoma that has been resequently resected; (this diet is not intended for neoadjuvant treatment)", "4 + knots", "OR if 1-3 + knots, either ER OR HER-2/neu+", "OR have a high risk node negative disease that is HER-2/neu positive OR >= 2.0 cm tumour size", "HER-2/new + definition: the patient has a known tumour HER-2/new expression = 3+ by IHC or, if 2+ by IHC confirmed to be positive FISH", "Patients with clinically apparent heart disease or similar history are not eligible; patients >= 60 years of age or with a history of hypertension must have an echocardiogram or MUGA prior to registration; patients with breast cancer who is HER-2/neu positive and a treatment plan that includes Herceptin must have an echocardiogram or MUGA scanner prior to registration; the LVEF must be within the normal institutional range; if the LVEF is > 75%, the investigator should consider having the LVEF examined or repeat MUGA prior to registration.", "WBC >= 4,000", "ANC >= 1,500", "Number of platelets >= 100 000", "Serum creatinine = < 1.5 x IULN", "Bilirubin = < 2.0", "SGOT/SGPT/alkaline phosphatase = < 2 x IULN", "\u2022 Higher elevations require metastatic work", "To be informed of the investigational nature of this study and to provide written informed consent in accordance with institutional and federal guidelines before considering specific screening procedures.", "- Exclusion criteria:", "With the exception of the following, no other malignancy is permitted: ipsilateral synchronous breast cancer of the same subtype (ER/PR, HER-2/neu), skin cancer of properly treated basal or squamous cells, in situcervical cancer or other stage I or II cancer whose patient has been free for at least 5 years.", "Patients with heart disease who would prevent the use of Adriaticin, Taxol or Herceptin are not eligible; this includes:", "Angina pectoris which requires the use of anti-anginal medicines", "Cardiac arrhythmia requiring medication", "\u2022 Severe abnormality of conduction", "Clinically significant valvular disease", "Cardiomegaly on chest x-ray", "- Ventricular hypertrophy on EKG", "Uncontrolled hypertension (diastolic > 100 mm/Hg or systolic > 200 mm/hg)", "The current use of digitalis or beta-blockers for CHF", "Clinically significant pericardial infusion", "A myocardial infarction documented as a clinical diagnosis or by EKG or any other test", "Documented congestive heart failure", "Documented cardiomyopathy", "Arrhythmia or documented heart valve disease that requires medication or is medically significant", "Patients who have already received chemotherapy or radiation therapy are not eligible.", "Pregnant or lactating patients are not eligible; women of childbearing potential must agree to use adequate contraception.", "Patients with active infection are not eligible", "Patients known to be infected with HIV, hepatitis B or hepatitis C are not eligible; screening is not required unless there is a high indication of clinical suspicion.", "Patients with psychiatric disorders are not eligible"], "Results": ["Performance measures:", "\u2022 Disease-free survival after a weekly high-dose diet of Adriaticin + oral cyclophosphamide increased with G-CSF support followed by Abraxane and Herceptin", "[Unspecified]", "Time limit: 2 years", "Results 1:", "Title of the arm/group: Arm I", "Patients receive high-dose chemotherapy including doxorubicin IV hydrochloride for 10-15 minutes on day 1, oral cyclophosphamide once daily on days 1-7, and filgrastim subcutaneously on days 2-7. Courses are repeated every 7 days for 12 weeks in the absence of disease progression or unacceptable toxicity. Starting a week later, patients receive a formulation of nanoparticles stabilized with paclitaxel IV albumin for 30 minutes once weekly for 12 weeks in the absence of disease progression or unacceptable toxicity.", "Doxorubicin hydrochloride: IV", "cyclophosphamide: administered orally", "- filgrastim: seen SC", "Formulation of nanoparticles stabilized by paclitaxel albumin:", "Trastuzumab: under IV", "Analysis of laboratory biomarkers: related studies", "Quality of Life Assessment: Auxiliary Studies", "Total number of participants analysed: 60", "Type of measure: Number of participants", "Unit of measure: Participants 56 93.3%"], "Adverse Events": ["Undesirable Events 1:", "Total: 5/60 (8.33 per cent)", "Febrile Neutopenia1/60 (1.67%)", "Haemorrhoidal haemorrhage1/60 (1.67%)", "- Mucosite1/60 (1.67%)", "Fever1/60 (1.67%)", "Pneumonstis Pneumonia1/60 (1.67%)", "Dehydration1/60 (1.67%)", "Musculoskeletal chest pain1/60 (1.67%)", "Pneumothorax due to MVA1/60 (1.67%)"]}